US › Healthcare

ProKidney Corp. (PROK)

US · Healthcare · Biotechnology

$1.63+4.49%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$226,000
Revenue YoY
-1.7%
Net profit
$-22.6M
Profit YoY
-35.0%
EPS
$-0.14
EPS estimate
$-0.14
Net margin
-9,992.9%

EPS came in at -0.14 against a street estimate of -0.14 — a miss of 1.8%.

Key statistics

Market cap
$471.2M
Forward P/E
0.0
P/B
97.15
Book value
$-7.21
EPS (TTM)
$-0.53
52-week high
$3.48
52-week low
$1.45
50-day MA
$1.73
200-day MA
$2.11
Beta
1.72

Analyst view

Analysts rate ProKidney Corp. a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $6.25.

Shareholding

Insiders
47.30%
Institutions
24.73%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC6.02%
Morgan Stanley - Brokerage Accounts4.37%
Millennium Management LLC1.11%
Bleichroeder LP0.98%
Hennion & Walsh Asset Management Inc0.90%
Artia Global Partners LP0.88%
BlackRock Inc0.68%
Renaissance Technologies Corp0.61%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ProKidney Corp. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.